Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Oral versus intravenous ibuprofen for the early closure of patent ductus arteriosus in low birth weight preterm infants

Alketa Hoxha, Ermira Kola, Numila Kuneshka, Eduard Tushe

. 2013 ; 2013 (6) : 14-19.

Jazyk angličtina Země Česko Médium elektronický zdroj

Perzistentní odkaz   https://www.medvik.cz/link/bmc14060603

Background Patent ductus arteriosus (PDA) is common in very premature infants. Pharmacological closure of PDA with indomethacin, a prostaglandin inhibitor, has remained the mainstay of treatment in premature infants over the last three decades. Intravenous ibuprofen was recently shown to be as effective and to have fewer adverse reaction in preterm infants. If equally effective, then oral ibuprofen for PDA closure would have several important advantages over the intravenous route. This study was designed to assess the efficacy and safety of oral ibuprofen and intravenous ibuprofen for the early pharmacological treatment of PDA in LBW preterm infants with respiratory distress syndrome. Methods A randomized, single-blinded, controlled study was performed on premature neonates at the neonatal care unit of the University Hospital for Obstetrics and Gynecology”Koco Gliozheni”, Tirana, Albania, from January 2010 to December 2012. The study enrolled 68 preterm infants with gestational age between 28-32 weeks, birth weight ≤ 2000 g, postnatal age 48-96 h, and had echocardiographically confirmed significant PDA. The preterm infants received either intravenous or oral ibuprofen randomly as an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h. After the first dose of treatment in both groups, echocardiographic evaluation was performed, to determine the need for a second or third dose. The rate of ductal closure, adverse effects, complications, and the patient’s clinical course were recorded. Results All patients were born after 28 until 32 weeks’ gestation. 36 patients were treated with oral ibuprofen and 32 with intravenous ibuprofen in this period. After the first course of the treatment, the PDA closed in 30 (83.3%) of the patients assigned to the oral ibuprofen group versus 23 (71.8%) of those enrolled in the intravenous ibuprofen group (p = 0.355). There was no difference between treatment groups in demographics or baseline renal function. In the evaluation of renal tolerance, none of the patients had oliguria. There were no significant differences with respect to complications during the stay. Conclusions In low birth weight infants, the rate of early ductal closure with oral ibuprofen is at least as good as with the intravenous route. Oral ibuprofen is associated with fewer adverse effects

Oral versus intravenous ibuprofen for the early closure of patent ductus arteriosus in low birth weight preterm infants [elektronický zdroj] /

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc14060603
003      
CZ-PrNML
005      
20140807111738.0
007      
cr|cn|
008      
140606s2013 xr d fs 000 0eng||
009      
eAR
024    7_
$a 10.12955/emhpj.v6i0.388 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Hoxha, Alketa $u University Hospital for Obstetrics and Gynecology, Tirana, Albania
245    10
$a Oral versus intravenous ibuprofen for the early closure of patent ductus arteriosus in low birth weight preterm infants $h [elektronický zdroj] / $c Alketa Hoxha, Ermira Kola, Numila Kuneshka, Eduard Tushe
504    __
$a Literatura
520    9_
$a Background Patent ductus arteriosus (PDA) is common in very premature infants. Pharmacological closure of PDA with indomethacin, a prostaglandin inhibitor, has remained the mainstay of treatment in premature infants over the last three decades. Intravenous ibuprofen was recently shown to be as effective and to have fewer adverse reaction in preterm infants. If equally effective, then oral ibuprofen for PDA closure would have several important advantages over the intravenous route. This study was designed to assess the efficacy and safety of oral ibuprofen and intravenous ibuprofen for the early pharmacological treatment of PDA in LBW preterm infants with respiratory distress syndrome. Methods A randomized, single-blinded, controlled study was performed on premature neonates at the neonatal care unit of the University Hospital for Obstetrics and Gynecology”Koco Gliozheni”, Tirana, Albania, from January 2010 to December 2012. The study enrolled 68 preterm infants with gestational age between 28-32 weeks, birth weight ≤ 2000 g, postnatal age 48-96 h, and had echocardiographically confirmed significant PDA. The preterm infants received either intravenous or oral ibuprofen randomly as an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h. After the first dose of treatment in both groups, echocardiographic evaluation was performed, to determine the need for a second or third dose. The rate of ductal closure, adverse effects, complications, and the patient’s clinical course were recorded. Results All patients were born after 28 until 32 weeks’ gestation. 36 patients were treated with oral ibuprofen and 32 with intravenous ibuprofen in this period. After the first course of the treatment, the PDA closed in 30 (83.3%) of the patients assigned to the oral ibuprofen group versus 23 (71.8%) of those enrolled in the intravenous ibuprofen group (p = 0.355). There was no difference between treatment groups in demographics or baseline renal function. In the evaluation of renal tolerance, none of the patients had oliguria. There were no significant differences with respect to complications during the stay. Conclusions In low birth weight infants, the rate of early ductal closure with oral ibuprofen is at least as good as with the intravenous route. Oral ibuprofen is associated with fewer adverse effects
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a novorozenec $7 D007231
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a prospektivní studie $7 D011446
650    _2
$a novorozenec nedonošený $7 D007234
650    12
$a novorozenec s nízkou porodní hmotností $7 D007230
650    _2
$a nemoci nedonošenců $x farmakoterapie $7 D007235
650    12
$a otevřená tepenná dučej $x farmakoterapie $7 D004374
650    12
$a ibuprofen $x aplikace a dávkování $x škodlivé účinky $7 D007052
650    12
$a aplikace orální $7 D000284
650    12
$a intravenózní podání $x statistika a číselné údaje $7 D061605
650    _2
$a gestační stáří $7 D005865
650    _2
$a porodní hmotnost $7 D001724
650    _2
$a barevná dopplerovská echokardiografie $7 D018618
650    _2
$a oligurie $x chemicky indukované $7 D009846
650    _2
$a výsledek terapie $7 D016896
650    _2
$a statistika jako téma $7 D013223
650    _2
$a kreatinin $x krev $7 D003404
650    _2
$a dusík močoviny v krvi $7 D001806
700    1_
$a Kola, Ermira $u University Hospital for Obstetrics and Gynecology, Tirana, Albania
700    1_
$a Kuneshka, Numila $u University Hospital for Obstetrics and Gynecology, Tirana, Albania
700    1_
$a Tushe, Eduard $u University Hospital for Obstetrics and Gynecology, Tirana, Albania
773    0_
$t European medical, health and pharmaceutical journal $x 1804-5804 $g Roč. 2013, č. 6 (2013), s. 14-19 $w MED00177703
856    41
$u https://ojs.journals.cz/index.php/EMHPJ/issue/view/47 $y plný text volně přístupný
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20140606091057 $b ABA008
991    __
$a 20140807112051 $b ABA008
999    __
$a ok $b bmc $g 1027824 $s 859253
BAS    __
$a 3 $a 4 $a PRD
BMC    __
$a 2013 $b 2013 $c 6 $d 14-19 $i 1804-5804 $m European Medical, Health and Pharmaceutical Journal $n Eur. Med. Health Pharm. J. $x MED00177703
LZP    __
$c NLK188 $d 20140807 $a NLK 2014-09/pk

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...